News
CRIS
10.87
0.00%
0.00
Weekly Report: what happened at CRIS last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at CRIS last week (0311-0315)?
Weekly Report · 03/18 12:17
Weekly Report: what happened at CRIS last week (0304-0308)?
Weekly Report · 03/11 12:12
Curis (CRIS) Gets a Buy from Truist Financial
TipRanks · 03/08 12:15
Weekly Report: what happened at CRIS last week (0226-0301)?
Weekly Report · 03/04 12:16
Weekly Report: what happened at CRIS last week (0219-0223)?
Weekly Report · 02/26 12:36
Weekly Report: what happened at CRIS last week (0212-0216)?
Weekly Report · 02/19 12:39
Weekly Report: what happened at CRIS last week (0205-0209)?
Weekly Report · 02/12 12:23
Curis Inc. Is Worried About This – Should You Be Worried Too?
TipRanks · 02/10 06:00
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
Telsey Advisory Group raised the price target for Ralph Lauren Corporation from $165 to $195. HSBC cut Bunge Global SA's price target from $122 to $105. Inotiv shares jumped 16.8% to close at $4.30 on Thursday. Wells Fargo cut Everest Group, Ltd. Price target.
Benzinga · 02/09 13:11
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Curis (CRIS)
TipRanks · 02/09 13:10
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
TipRanks · 02/09 11:20
Curis Price Target Cut to $26.00/Share From $51.00 by HC Wainwright & Co.
Dow Jones · 02/09 11:18
Curis Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/09 11:18
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $26
Benzinga · 02/09 11:07
Curis files for $300M common stock offering
Seeking Alpha · 02/08 21:39
Curis Inc reports results for the quarter ended in December - Earnings Summary
Curis Inc reports results for the quarter ended in December. Revenue fell 6.6% to $2.70 million from a year ago. The company reported a quarterly loss of $11.71 million. Curis Inc shares had fallen by 26.4% this quarter.
Reuters · 02/08 17:14
Curis Inc Q4 sales decline
NASDAQ · 02/08 13:20
*Curis: As of Dec 31, Cash, Cash Equivalents and Investments Totaled $56.3M >CRIS
Dow Jones · 02/08 13:03
Curis GAAP EPS of -$2.03 beats by $0.09, revenue of $2.7M misses by $0.38M
Earnings News Curis GAAP EPS of -$2.03 beats by $0.09, revenue of $2.7M misses by $ 0.38M. Curis expects its existing cash, cash equivalents and investments should enable its planned operations into 2025.
Seeking Alpha · 02/08 13:02
More
Webull provides a variety of real-time CRIS stock news. You can receive the latest news about Curis through multiple platforms. This information may help you make smarter investment decisions.
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.